Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2012 | 01:16am CET

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
03/24 GLOBAL GASTROINTESTINAL DRUGS MARKET : Abbott Laboratories, Allergan, AstraZenec..
03/23 ASTRAZENECA : and Circassia to Develop COPD Inhalants
03/22 ASTRAZENECA : gets second CRL for Zs-9 after Zs Pharma plant inspection
03/21 ASTRAZENECA : CVD-REAL study shows SGLT-2 inhibitors significantly reduced death..
03/21 CIRCASSIA PHARMACEUTICALS : to acquire US rights to Tudorza and Duaklir from Ast..
03/20 FTSE rises to record close after Article 50 trigger date set
03/20 ASTRAZENECA : and Circassia enter strategic collaboration in respiratory disease
03/20 ASTRAZENECA : receives Complete Response Letter from US FDA for ZS-9 (sodium zir..
03/20 ASTRAZENECA : Sheriffs conduct public safety drill at MedImmune facility in Fred..
03/20 ASTRAZENECA : AZ reports fewer heart deaths from use of Type 2 diabetes drug
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/23 Pharma Development Budgets Grow As Roche Remains A Believer
03/21 AstraZeneca's Mistakes Mount
03/21 Biotechs under pressure after Trump (again) decries high drug prices
03/21 Jardiance Heart Benefit Looks Like A Class Effect
03/20 Real-world study shows type 2 diabetics treated with SGLT-2 inhibitors experi..
Advertisement
Financials ($)
Sales 2017 21 453 M
EBIT 2017 5 694 M
Net income 2017 2 567 M
Debt 2017 12 101 M
Yield 2017 4,44%
P/E ratio 2017 30,89
P/E ratio 2018 22,28
EV / Sales 2017 4,22x
EV / Sales 2018 4,08x
Capitalization 78 333 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 63,5 $
Spread / Average Target 2,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC11.76%78 333
JOHNSON & JOHNSON9.28%341 301
ROCHE HOLDING LTD.7.52%219 164
PFIZER INC.5.57%204 201
NOVARTIS AG-0.94%196 550
MERCK & CO., INC.7.49%173 740
More Results